Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) EBITDA Margin (2017 - 2025)

VYNE Therapeutics' EBITDA Margin history spans 9 years, with the latest figure at 5757.0% for Q2 2025.

  • For Q2 2025, EBITDA Margin fell 106000.0% year-over-year to 5757.0%; the TTM value through Jun 2025 reached 7636.71%, down 162721.0%, while the annual FY2025 figure was 4649.3%, 331870.0% up from the prior year.
  • EBITDA Margin reached 5757.0% in Q2 2025 per VYNE's latest filing, down from 4315.5% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3234.58% in Q2 2021 to a low of 27531.03% in Q4 2022.
  • Average EBITDA Margin over 5 years is 7748.88%, with a median of 6115.74% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: tumbled -2429074bps in 2022, then soared 1942314bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 3240.29% in 2021, then crashed by -750bps to 27531.03% in 2022, then skyrocketed by 71bps to 8107.89% in 2023, then plummeted by -79bps to 14501.2% in 2024, then skyrocketed by 60bps to 5757.0% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's EBITDA Margin are 5757.0% (Q2 2025), 4315.5% (Q1 2025), and 14501.2% (Q4 2024).